跳至主要内容
临床试验/NL-OMON42953
NL-OMON42953已完成不适用

An open label positron emission tomography (PET) imaging study using 89-Zirconium labelled GSK3128349 to investigate the biodistribution and clearance of an albumin binding domain<br>antibody (AlbudAb) GSK3128349 following single dose intravenous administration in healthy male subjects. - AlbudAb PET study.

GlaxoSmithKline Research & Development Limited0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • healthy male subjects
  • 50 - 65 years of age, inclusive
  • BMI 19.0 - 31.0 kilograms/meter2
  • non smokers or less than 5 cigarettes per day

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

相似试验